EAU 2018 Prostate Cancer

EAU 2018: Hormone-Naive Prostate Cancer

Copenhagen, Denmark (UroToday.com) Dr. Joniau gave an overview of hormone-naïve prostate cancer (HNPC). Approximately 5% of the screened population present with de novo metastatic prostate cancer. This represents 1/3 of the prostate cancer (PC) death in the USA each year. The remaining 2/3 of patients relapse after prior localized therapy. They undergo rapid progression to metastasis, with transformation of HSPC to castrate resistant prostate cancer (CRPC), and then to death. The median time from radical prostatectomy to PSA failure is 24 months (12-44). The median time from PSA failure to metastasis is 32 months (2-129), and finally the median time from metastasis to PC specific mortality is 82 months (7-181). Overall, from PC relapse to PC specific death the median time is 132 months (12-204).

EAU 2018: Castration Resistant Prostate Cancer

Copenhagen, Denmark (UroToday.com) Dr. Evans gave an overview of the hottest and latest news in the medical treatment of castrate resistant prostate cancer (CRPC). In metastatic CPRC (MCRPC), plasma circulating tumor DNA (ctDNA) has emerged as a tool to sample the tumor genome. Up until recently, no systematic comparisons of matched liquid and solid biopsies were performed to enable ctDNA profiling to replace direct tissue sampling.

EAU 2018: Culture-based Targeted Antibiotic Prophylaxis By Β-lactams Alone is Not Sufficient to Prevent Infective Complications After Transrectal Prostate Biopsy

Copenhagen, Denmark (UroToday.com) Dr. Nasu, a clinical urologist from the Okayama Rosai Hospital, Dept. of Urology, presented on the efficacy of targeted antibiotic prophylaxis (TAP) by use of beta-lactams to prevent infective complications (IC) after transrectal ultrasonography guided prostate biopsy (TRPB) in patients with quinolone-resistant E. coli (QREC).

EAU 2018: Morbidity Evaluation of Antiplatelet and Anticoagulant Treatments According to Their Perioperative Management During Photovaporisation of the Prostate by Greenlight Laser

Copenhagen, Denmark (UroToday.com) Dr. B. Pradere, clinical urologist from the CHU Tours in Tours, France, shared his findings on the feasibility of photovaporizaiton of the prostate (PVP) by Greenlight laser for patients who are unable to undergo surgery without taking antiplatelet (AP) or anticoagulant (AC) medications.

EAU 2018 - Prostate Specific Antigen (PSA) Response in Men With Nonmetastatic Castration-Resistant Prostate Cancer (M0 CRPC) Treated With Enzalutamide: Results From PROSPER

Copenhagen, Denmark (UroToday.com) M0 CRPC or nmCRPC is an area of unmet need. Development of metastases is associated with increasing baseline PSA and PSA doubling time <10 months. ^2-3 Median metastasis-free survival (MFS) was 25-30 months in the placebo arms of several randomized controlled trials.^1-3 Delaying time to all metastases is clinically relevant, with potential to delay cancer-related morbidity and prolong overall survival (OS). ⁴Enzalutimide significantly improved OS and radiographic progression-free survival (rPFS) in men with chemotherapy-naive M1 CRPC in the phase 3 PREVAIL study. ⁵ Enzalutimide was superior to bicalutamide in improving rPFS in the subgroup of patients with chemotherapy-naive M0 CRPC in the phase 2 STRIVE study.⁶ We hypothesized that enzalutimide will delay metastases development in men with M0 CRPC and rapidly rising PSA (PSA doubling time 2265≤ 10 months).

EAU 2018: Case-Based Debate BRCA 1/2 Testing Before Treatment of Metastatic Castration-Resistant Prostate Cancer - Not Yet

Copenhagen, Denmark (UroToday.com) Dr. Hamdy presented is view on why it is still not the right time for genetic testing of metastatic castrate resistant prostate cancer (MCRPC) patients. There are 5 things an MCRPC patient wants to know:

EAU 2018: Case-Based Debate: BRCA 1/2 Testing Before Treatment of Metastatic Castration-Resistant Prostate Cancer - Ready for Prime Time

Copenhagen, Denmark (UroToday.com) Dr. Nelson gave an overview of why BRCA 1 and 2 testing should be done before treatment of metastatic castrate resistant prostate cancer (MCRPC) patients. His talk summarized 10 points on why it is prime time for genetic testing before treating these patients.

Page 1 of 13

EAU 2018 Prostate Cancer

Stay Connected

Login